FDA grants priority review for iberdomide-based myeloma regimen
1. The FDA has granted priority review for iberdomide, a first-in-class oral CELMoD designed to degrade transcription factors more effectively ...
Tag: multiple myeloma
2 Minute Medicine Rewind
Ultrasound-Guided Regional Anesthesia by Emergency Physicians for Hip Fractures and Delirium 1. An intervention to increase point-of-care ultrasound-guided regional anesthesia ...
Pre-maintenance positron emission tomography/computed tomography and bone marrow multiparameter flow cytometry are important for prognostication in multiple myeloma treated with daratumumab
1. Pre-maintenance positron emission tomography (PET)/computed tomography (CT) and bone marrow multiparameter flow cytometry (BM MFC) are associated with better ...
The Scan by 2 Minute Medicine®: Shoulder scalpel, shark scare, Alzheimer dosing tweak, and a Blenrep blow
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. Will ...
Talquetamab and teclistamab combination improved response in relapsed multiple myeloma
1. In this randomized controlled trial, in patients with relapsed or refractory multiple myeloma (MM), combination therapy of talquetamab and ...
#VisualAbstract: Daratumumab Reduces Risk of Progression in High-Risk Smoldering Multiple Myeloma
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients
Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ineligible ...
#VisualAbstract: Belantamab Mafodotin in Combination with Standard-Care Therapies Improved Progression-Free Survival in Patients with Multiple Myeloma Compared to Standard-Therapy Alone
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may ...
Johnson & Johnson and Legend Biotech’s Carvykti shows improved survival in treatment-experienced multiple myeloma patients
As a 2nd line therapy for multiple myeloma, Carvykti can lower the risk of disease progression or death by 59% ...
Daratumumab linked to improved progression-free survival and MRD-negativity in transplant-eligible myeloma patients
1. Daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) as induction and consolidation therapy led to superior progression-free survival ...
